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Abstract 
 
Background: Pulmonary arterial hypertension (PAH) remains a serious disease characterized 
by elevated pulmonary artery pressure (PAP) and increased pulmonary vascular resistance 
(PVR).  Among the subtypes of PAH, PAH associated with connective tissue disease 
(CPAH) has the worse prognosis due to resistance to conventional vasodilator therapy.  I 
hypothesized that the intensive immunosuppressive therapy (IIT) could improve pulmonary 
hemodynamics in CPAH.  Methods and Results: In our pulmonary hypertension (PH) 
cohort with 182 patients, I evaluated 13 consecutive patients with CPAH, who received IIT 
combined with cyclophosphamide and glucocorticosteroids (IIT group, mean age 45±8 years, 
12 females and 1 male).  I compared them with 8 historical controls (control group: mean 
age 52±18 years, 8 females) for pulmonary hemodynamics and prognosis.  Both groups were 
treated with conventional vasodilator therapy.  Although mean PAP (mPAP) remained 
unchanged in the control group, IIT significantly decreased mPAP (40±9 to 29±11 mmHg, 
P<0.01) and tended to decrease PVR (700±434 to 481±418 dyne*sec/cm5, P=0.07).  
Importantly, in 6 out of the 13 patients of the IIT group, mPAP was almost normalized (<25 
mmHg) and remained stabilized for more than a year.  Furthermore, the IIT group showed 
significantly better prognosis compared with the control group (P<0.01).  Conclusions: 
These results suggest that the intensive immunosuppressive therapy on the top of 
conventional vasodilator therapy improves pulmonary hemodynamics and long-term 
prognosis of patients with CPAH.   
 (220 words) 
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Introduction 
 
Pulmonary arterial hypertension (PAH) is a serious condition caused by small pulmonary 
artery obstruction due to vascular proliferation and remodeling,1-3 defined as a mean 
pulmonary arterial pressure (mPAP) greater than 25 mmHg at rest.4, 5 Although it is unclear 
whether the various types of PAH share a common pathogenesis, at least three common 
factors are thought to increase PVR that characterizes this disorder, which are pulmonary 
vasoconstriction, remodeling of the pulmonary arterial wall, and thrombosis in situ. A new 
classification of clinical pulmonary hypertension (Dana point 2008, Table 1) has been 
recently updated,5 which designated 5 categories as described below.  
Group 1, pulmonary arterial hypertension (PAH), is a clinical condition defined as 
mean PAP ≥ 25 mmHg and pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, which 
is characterized by the presence of pre-capillary PH in the absence of other causes of 
pre-capillary PH, such as PH due to lung diseases, chronic thromboembolic PH (CTEPH) or 
other rare diseases (Figure 1, Table 1).  Pulmonary veno-occlusive diseases and/or 
pulmonary capillary hemangiomatosis (Group 1’) should be a distinct category but not 
completely separated from PAH as they share similar characteristics with idiopathic PAH 
(IPAH) but demonstrate some differences.  
Group 2, PH due to left heart disease, is characterized by the passive backward 
transmission of the pressure elevation (post-capillary PH). There are 2 types of post-capillary 
PH; one is the normal transpulmonary pressure gradient (TPG, determined as mean PAP 
minus mean PCWP) and PVR, which is defined as the passive post-capillary PH, while the 
other is the elevated TPG and PVR, the reactive post-capillary PH (“out of proportion” PH) 
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(Figure 1, Table 1).  
Group 3, PH due to lung diseases and/or hypoxia, is caused by hypoxic 
vasoconstriction as a result of lung diseases, in which PH is generally modest (mean PAP 25 
to 35 mmHg).  
Group 4, CTEPH is caused by chronic and mechanical obstruction of central and/or 
distal pulmonary arteries due to thromboembolic masses (Figure 1, Table 1).   
Group 5 consists of several remaining forms of PH, for which the etiology is unclear 
and may be multifactorial (Figure 1, Table 1).   
Among the subtypes of PAH (Group 1), connective tissue disease-associated PAH 
(CPAH) has the worse prognosis due to resistance to conventional vasodilator therapy as 
evidenced by the fact that patients with systemic sclerosis (SSc) had a 1-year survival rate of 
only 45% before the introduction of advanced vasodilator therapies.6  Although several 
vasodilators, anticoagulant agents and lung transplantation are currently used for the 
treatment of CPAH, more effective treatment needs to be developed.7-9   
 It is widely accepted that immunological and inflammatory mechanisms contribute to 
the progression of PAH in patients with connective tissue disease (CTD), such as SSc, 
systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD).10, 11  
Indeed, inflammatory cells (e.g. macrophages and lymphocytes) were detected in the 
plexiform lesions in the lung from CPAH patients.12, 13  It has been recently reported that 
immunosuppressive therapy combined with cyclophosphamide and glucocorticosteroids is 
effective in patients with SLE or MCTD, where half of the patients responded to the first line 
of immunosuppressive therapy alone showed improvement in symptoms, exercise tolerance 
and pulmonary hemodynamics.14, 15 However, the immunosuppressive therapy alone without 
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vasodilators did not normalize mPAP in those patients.14, 15   
Thus, in the present study, I tested the hypothesis that the intensive 
immunosuppressive therapy combined with cyclophosphamide and glucocorticosteroids on 
the top of vasodilator therapy can improve pulmonary hemodynamics and long-term 
prognosis in patients with CPAH.      
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Methods 
 
The study protocol was approved by the Ethical Committees of Tohoku University and all 
patients provided written informed consent.   
 
Cohort of PH Patients 
Our cohort consisted of 182 consecutive patients with PH who admitted to our Tohoku 
University Hospital from 1974 to 2010 (Figure 2).16  They were regularly followed up  
every half to one year by various examinations including cardiac catheterization.16  Besides 
this regular follow-up, They were hospitalized when their symptoms or right heart failure 
worsen.16   
 
Diagnosis of PH Subtypes 
We performed right heart catheterization in all 182 patients with PH, in whom PH was 
defined as mPAP greater than 25 mmHg at rest.4, 5  The definition of PAH adds the criterion 
that the pulmonary arterial wedge pressure (PCWP) must be ≤15 mmHg.4, 5, 17  Connective 
tissue disease and liver disease were diagnosed clinically and by blood tests, as defined by 
each criteria.18-26  Congenital heart disease-associated PH (CHD-PH) was diagnosed by 
echocardiography and chronic thromboembolism-associated PH (CTEPH) by 
ventilation-perfusion RI scans and computed tomography (CT).  Pulmonary function tests, 
arterial blood gases, chest X-ray and CT scan were used to diagnose lung disease and hypoxia.  
When the above-mentioned abnormalities were ruled out, the patients were diagnosed as 
idiopathic PAH (IPAH).5, 17, 27  Heritable PAH was diagnosed as IPAH with family history 
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of PAH.5, 17, 27, 28  Pulmonary veno-occlusive disease (PVOD) was diagnosed by pathological 
examination or suspected by high-resolution CT scan.29   
 
Patients Inclusion 
Based on the criteria mentioned above, the subtypes of PH were diagnosed, including IPAH 
(n=51), heritable PAH (n=3), CPAH (n=32), congenital heart diseases (CHD-PAH, n=30), 
portal hypertension (porto-PH, n=11), PVOD (n=4), and CTEPH (n=51) (Figure 2).   
Among the 32 patients with CPAH, 11 patients were excluded because they were 
unable to follow up with right heart catheterization by the end of December 2010 (Figure 2).  
Among the remaining 21 patients with CPAH, 13 consecutive patients were treated with the 
intensive immunosuppressive therapy (IIT group) since 2007, whereas 8 patients were treated 
with CPAH with conventional vasodilator therapy alone before 2007 (historical control 
group) (Figure 2).  The follow-up period was 914±456 days for the historical control group 
and 565±431 days for the IIT group.  
 
Data Collection  
Baseline demographic information (age, gender, height and body weight), clinical diagnosis, 
comorbidities (connective tissue diseases, liver diseases, congenital heart diseases, and 
thyroid dysfunciton), plasma levels of brain natriuretic peptide (BNP), 6-minute walking 
distance and hemodynamic data from catheterization were recorded for each patient.  
Hemodynamic parameters examined included PCWP, pulmonary artery pressure (PAP), right 
ventricular end-diastoilc pressure (RVEDP), right atrial pressure (RAP), cardiac output (CO), 
cardiac index (CI), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood 
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pressure (mBP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR) 
and mixed venous oxygen saturation (SVO2).  All cause death or cardiovascular death was 
also recorded.   
 
Intensive Immunosuppressive Therapy for CPAH  
Because it has been demonstrated that the immunosuppressive therapy with combined with 
cyclophosphamide and glucocorticosteroids is effective in patients with SLE or MCTD, I 
selected the intensive immunosuppressive therapy (IIT) as a combination therapy with 
cyclophosphamide (500 mg IV 10 times in a year, once a month for the first 3 months 
followed by once in 1-3 months) and glucocorticosteroids (1 mg/kg/day PO in the first month, 
followed by gradual tapering afterward by 5-10 mg/day in each 2-4 weeks with a maintenance 
dose of 5-10 mg/day) (Figure 3).  Cyclophosphamide is an inactive merchlorethamine 
derivative that undergoes extensive metabolism by cytochrome P450 in the liver or other 
tissues, such as transitional epithelial cells of bladder or lymphocytes, to form active 
alkylating (4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein ) and inactive 
products. Right heart catheterization was performed in all patients at baseline and every half 
to one year during the follow-up period (Figure 3).  Hemodynamic responders were defined 
when mPAP was reduced to <25 mmHg or >10% reduction of baseline value.  By contrast, 
Control group has received immunosuppressive therapy with oral glucocorticosteroids (1 
mg/kg/day or less), one of whom has combined low dose of oral Cyclophosphamide (50 
mg/day) (Figure 4). 
 
Vasodilator Therapy for CPAH  
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All patients were treated with pulmonary vasodilators including intravenous prostacylcine, 
oral prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors, and endothelin 
(ET)-receptor blocker (bosentan).  
Prostacyclin: Prostacyclin is produced by endothelial cells from prostaglandin H2 by 
the enzyme prostacyclin synthase.  Prostacyclin and prostacyclin analogs are potent 
vasodilators and have antithrombotic, antiproliferative, and anti-inflammatory effects.  
PDE-5 inhibitors: Another strategy for increasing the activity of endogenous nitric 
oxide in PAH is to enhance nitric oxide-dependent, cyclic guanosine monophosphate 
(cGMP)-mediated pulmonary vasodilatation through inhibition of the breakdown of cGMP by 
PDE type5.  PDE-5 inhibitors, such as sildenafil, have an acute pulmonary vasodilator 
effect.  
ET-receptor antagonists: In addition to exerting a direct vasoconstrictor effect, 
endothelin-1 stimulates the proliferation of vascular smooth-muscle cells, acts as a 
co-mitogen, induces fibrosis, and is a proinflammatory mediator by virtue of its capacity to 
enhance the expression of adhesion molecules.  The effects of endothelin-1 are mediated 
through the ETA and ETB endothelin receptors. Bosentan is an orally active dual (ETA and 
ETB) endothelin-receptor antagonist. 
The patients usually start to take the oral prostacyclin (beraprost) at a starting dose of 
60 g/day and increase the dose in a stepwise manner up to 240 g/day, when tolerable.16  In 
the daily practice, they usually start to take the intravenous prostacyclin (epoprostenol) 
therapy during hospitalization at a starting dose of 0.5~1 ng/kg/min.16  Thereafter, the dose 
of epoprostenol is carefully increased in a step-wise manner on the basis of symptoms and 
side effects of the drug.16  Similarly, PH patients were usually started with bosentan at 31.25 
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mg/day combined with dobutamine and/or milrinone with heart failure and 62.5 mg/day for 
those without heart failure, and then carefully increased the dose in a stepwise manner every 
week.16  Regarding sildenafil, they were usually started at 30 mg/day and increased the dose 
up to 60 mg/day when tolerated.16  Also, they were usually started at 20 mg/day of tadalafil 
and increased the dose up to 40 mg/day.  In the present study, the CPAH patients were 
treated with prostacyclin, bosentan, sildenafil, and tadalafil as a monotherapy or in 
combination and no difference in the vasodilator therapy was noted between the historical 
control and the IIT groups (Table 2).16   
 
Statistical Analysis 
Results are expressed as the mean ± SD.  Paired t-test was used for comparison of 
continuous variables and Fisher’s exact test for categorical variables.  Survival from 
all-cause/ cardiovascular death or lung transplantation was estimated by Kaplan–Meier 
method and differences between the curves were examined for significance using the log-rank 
test.  Statistical analyses were performed using GraphPad Prism 5.0E (GraphPad Software 
Inc, La Jolla, CA, USA).  P values less than 0.05 were considered to be statistically 
significant.   
 
山本沙織 博士論文, Page 11 
  
Results 
 
Clinical Characteristics of Patients with CPAH  
Clinical characteristics of the CPAH patients in the historical control and the IIT groups are 
shown in Table 2.  There were no significantly differences in baseline characteristics 
between the 2 groups except the use of phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil 
and tadalafil) and 6-minute walk distance (Table 2).   
 
Effects of IIT on Pulmonary Hemodynamics  
Although mPAP and PVR remained unchanged in the historical control group, IIT 
significantly reduced mPAP and tended to decrease PVR and plasma levels of BNP by the 
end of follow-up periods (Figure 5,6,7).  CI was well maintained in both groups by the end 
of follow-up periods (Figure 8).  In the historical control group, mPAP remained unchanged 
or progressively deteriorated with subsequent death in 5 of the 8 patients (Figure 9).  In 
contrast, in the IIT group, mPAP was progressively improved in 12 of the 13 patients and in 6 
of them, mPAP was normalized (Figure 9).  One patient in the IIT group died shortly after 
the initiation of the therapy (Figure 9).  In IIT and Control groups, all patients died of right 
heart failure, where one of them in Control group died in complication with disseminated 
intravascular coagulation (Figure 10). 
 
Effects of IIT on Long-term Survival  
The IIT group showed a markedly improved long-term survival as compared with the 
historical control group (Figure 11).  There was no PH-unrelated death or lung 
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transplantation in this study population.  
 
Elapsing Time from Diagnosis to First IIT and Response to IIT 
In most of the CPAH patients, the first intensive cyclophosphamide was started 2 to 4 months 
after the diagnosis.  However, the initiation of the IIT therapy was delayed in 1 patient with 
Sjogren syndrome (at 24 months) and 2 patients with SLE (at 60 and 108 months) after the 
diagnosis of CPAH (Figure 12).  In the present study, 3 out of the 13 patients with CPAH 
were diagnosed as non-responders, including one SLE, one Sjogren, and one SSc patient 
(Figure 12).  Only 2 out of the 13 patients had mild liver dysfunction as side effects of 
cyclophosphamide.  I did not observe any other side effects such as serious infections or 
some life-threatening complications.   
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Discussion 
 
The findings of the present study are that the intensive immunosuppressive therapy combined 
with cyclophosphamide and glucocorticosteroid on the top of conventional vasodilator 
therapy markedly improved pulmonary hemodynamics and long-term prognosis of patients 
with CPAH.  The effects of the intensive immunosuppressive therapy were evident when it 
was started immediately after diagnosis of CPAH.  The results suggest that the intensive 
immunosuppressive therapy with conventional vasodilator therapy in the early phase of 
CPAH is the promising therapeutic strategy for the fatal disorder.   
 
Current Therapy in CPAH  
The current treatment for CPAH follows the same treatment algorithm as in IPAH.17  The 
recommendation is based on the fact that most of the major trials for PAH therapy have 
included CPAH patients, in which intravenous epoprostenol therapy, bosentan, sitaxsentan, 
sildenafil, and subcutaneous treprostinil exerted favorable effects in CPAH.17  Also, the 
immunosuppressive therapy combined with cyclophosphamide and glucocorticosteroids 
showed the clinical improvement in SLE and MCTD-associated PAH.14, 15  However, none 
of the previous trials were able to normalize pulmonary hemodynamics in CPAH patients.  I 
should strengthen in the present study that my protocol of intensive immunosuppressive 
therapy responded in 10 out of 13patients (77%) and normalized pulmonary hemodynamics in 
6 out of the 13 patients was normalized to improve long-term prognosis of those patients.   
In the present study, I was able to normalize pulmonary hemodynamics in 6 out of 
the 13 patients and to improve long-term prognosis of those patients.  Further, it seems that 
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the patients with better response to the intensive immunosuppressive therapy in the first right 
heart catheterization had better responses in the chronic phase (Figures 9 and 12).  The 
protocol of the present immunosuppressive therapy is original for the following 2 points that I 
started the therapy combined with conventional vasodilator therapy in the early phase of the 
disorder regardless of immunological activity and that I used cyclophosphamide more 
frequently as compared with previous studies (Figure 3).14, 15   
 
Pulmonary Hemodynamics in CPAH Patients 
CPAH is one of the most malignant type of PH and there is only one case report in which 
pulmonary arterial pressure was normalized with conventional therapy.30  Indeed, in the 
present study, mPAP remained unchanged or progressively deteriorated in the historical 
control group treated with only pulmonary vasodilators and glucocorticosteroids and mPAP 
was improved only when intensive immunosuppressive therapy was added.  Thus, I consider 
that the combination of the immunosuppressive therapy with cyclophosphamide and 
glucocorticosteroids and conventional pulmonary vasodilator therapy is crucial to dilate 
pulmonary arteries and to ameliorate pulmonary arteriopathy in CPAH.   
The present immunosuppressive therapy was ineffective in a patient with 
SSc-associated PAH, a consistent finding of the previous studies.6, 31, 32  However, it has 
been recently reported that the combination therapy with imatinib and cyclophosphamide was 
well tolerated without major side effects in patients with SSC-associated interstitial lung 
disease.33  The effect of this combined immunosuppressive therapy for SSc-associated PAH 
remains to be examined in a future study.    
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Prognosis of CPAH Patients 
It has been reported that patients with CPAH have poorer prognosis than those with IPAH,34, 
35 and that the presence of PAH is a significant prognostic factor in connective tissue disease 
such as SLE, MCTD and SSc.6, 36, 37  To the best of our knowledge, the present study is the 
first study that demonstrates that the intensive immunosuppressive therapy could improve not 
only pulmonary hemodynamics but also long-term prognosis of patients with CPAH.    
 
Limitations of the Study 
Several limitations should be mentioned for the present study.  First, the present study is an 
observational cohort study from a single center.  Thus, the present finding regarding the 
effectiveness of the combination of the intensive immunosuppressive therapy and the 
conventional pulmonary vasodilator therapy remain to be confirmed in a large multi-center 
study.  Second, in the present study, the CPAH patients were treated individually, but not in 
a randomized manner, based on pulmonary hemodynamics and comorbidities.  Although 
there were no significant differences in pulmonary hemodynamics between the 2 groups, 
some cases might be more severe in Control group than in IIT group.  Further, less SLE 
patients were included in Control group, in whom IIT might be more effective than other 
CTD and more SSC were included in IIT group, in whom IIT might not be effective (7 SLE 
and 1 SSc in IIT group, and 1 SLE and 3 SSc in Control group).   However, it is difficult to 
perform a randomized study for those patients with the rare and fatal disorder.  Third, the 
previous study has shown that immunosuppressant and glucocorticoids could be successful in 
a subset of patients with SLE- or MCTD- associated PAH, but not in those with 
SSc-associated PAH.  The present study suggests that SSc may be resistant even to the 
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present combination therapy.  The effective therapy for SSc-associated PAH still remains to 
be developed.  Forth, the historical control group tended to have less chances to receive 
pulmonary vasodilator due to the availability of medicines, which may affect the pulmonary 
hemodynamics and prognosis.  Further, since there was a statistically significant difference 
in the treatment of phosphodiesterase type 5 inhibitors (PDE-5 inhibitors; sildenafil and 
tadalafil), it remains to be examined whether PDE-5 inhibitors combined with or without the 
immunosuppressive therapy can normalize pulmonary arterial pressure and improve the 
prognosis in future studies. Fifth, it is suggested that the prognosis of PAH is different among 
the underlying diseases of connective tissue diseases, such as SLE, SSc, and MCTD.  Thus, 
it is possible that the difference in underlying diseases of each group influenced the results of 
long-term prognosis of this study.  Further, the activity of each connective tissue disease was 
unable to be evaluated in the present study because of the following 2 major reasons; one was 
that reliable activity scoring system is not available for some connective tissue diseases.  The 
other was that there is a substantial variation in the activity of a given connective tissue 
disease.  Therefore, the correlation between the activity of connective tissue disease and the 
effects of the intensive immunosuppressive therapy was unable to be examined in the present 
study. 
 
Conclusions 
In the present study, I was able to demonstrate that the combination of the intensive 
immunosuppressive therapy with cyclophosphamide and glucocorticosteroids and the 
conventional pulmonary vasodilator therapy markedly improves pulmonary hemodynamics 
and long-term prognosis of patients with CPAH, possibly in the early phase of CPAH.  
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These results may develop a new treatment algorithm of CPAH in the near future (Figure 13). 
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Figure legends 
 
Figure 1.  Diagnosis and classification of pulmonary hypertension  
CT, computed tomography; CTEPH, chronic thromboembolic pulmonary hypertension; ECG, 
electrocardiogram; mPAP, mean pulmonary arterial pressure; OCT, optical coherence 
tomography; PAH, pulmonary hypertension; PCWP, pulmonary capillary wedge pressure; PH, 
pulmonary hypertrension.  
 
Figure 2.  Enrollment algorithm in the present study  
Of the 182 patients in our PH cohort, 32 were diagnosed as having CPAH.  We excluded 11 
out of the 32 patients with CPAH because we were unable to perform follow-up right heart 
catheterization by the end of December 2010.   
 
Figure 3.  The protocol of the present intensive immunosuppressive therapy  
The intensive immunosuppressive therapy (IIT) is a combination therapy with 
cyclophosphamide (500 mg IV ten times in a year, once a month for the first 3 months 
followed by once in 3 months) and glucocorticosteroids (1 mg/kg/day PO in the first month, 
followed by gradual tapering afterward by 5-10 mg/day in each 2-4 weeks with a maintenance 
dose of 5-10 mg/day).  Right heart catheterization was performed in all patients at baseline 
and every half to one year in the follow-up period.  CY, cyclophosphamide.  
 
Figure 5. Effects of IIT on mPAP in CPAH Figure 4. Pulmonary vasodilators and 
immunosuppressive therapy in control group  
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Control group has received immunosuppressive therapy with oral glucocorticosteroids (1 
mg/kg/day or less), one of whom has combined low dose of oral Cyclophosphamide (50 
mg/day) (Figure 4). 
 
 
In the historical control group, mPAP was slightly elevated during the follow-up period.  In 
contrast, the IIT therapy significantly reduced mPAP.   
 
Figure 6. Effects of IIT on PVR in CPAH 
In the historical control group, PVR remained unchanged during the follow-up period.  In 
contrast, the IIT therapy tended to decrease PVR.  
 
Figure 7. Effects of IIT on plasma levels of BNP in CPAH 
In the historical control group, plasma levels of BNP remained unchanged during the 
follow-up period.  In contrast, the IIT therapy tended to reduce BNP levels.   
 
Figure 8. Effects of IIT on CI in CPAH 
CI was well maintained in both groups.   
 
Figure 9. Effects of IIT on serial changes of mPAP in CPAH 
Mean PAP remained unchanged or progressively deteriorated in the historical control group, 
whereas it was progressively improved in the IIT group. 
Red bar; SLE, Blue; MCTD, Green; SSc, Purple; RA, Yellow; Sjogren and Black; DM.  
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Figure 10. Cause of death on IIT and control groups 
In IIT and Control groups, all patients died of right heart failure, where one of them in 
Control group died in complication with disseminated intravascular coagulation.   
 
Figure 11. Kaplan-Meier curves of IIT and control groups  
The survival curve from the diagnosis of CPAH was significantly better in the IIT group than 
the historical control group.  Five out of 8 patients in the historical control group and 1 out 
of 13 patients in the IIT group died of cardiovascular causes.  No lung transplantation was 
performed in those CPAH patients.   
CI, cardiac index; IIT, intensive immunosuppressive therapy; mPAP, mean pulmonary arterial 
pressure; PVR, pulmonary vascular resistance.   
 
Figure 12.  Elapsing time from diagnosis of CPAH to first IIT and response to IIT 
The effects of the intensive immunosuppressive therapy for PAH are evident when it was 
started immediately after the diagnosis of the disorder.  
 
Figure 13.  Potential new treatment algorithm for CPAH  
ETR, endothelin receptor; Fc,functional class; PG, prostaglandin; PDE-5, 
phosphodiesterase-5. 
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Table 1. Clinical Classification of Pulmonary Hypertension (Dana Point, 2008)* 
Group 1 – Pulmonary arterial hypertension (PAH) 
 Idiopathic PAH (IPAH) 
 Heritable PAH (HPAH) 
 Drug and toxin-induced 
Associated with connective tissue disease, HIV, portopulmonary hypertension, 
schistosomiasis, and chronic hemolytic anemia, etc. 
 
Group 1’ – Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
hemangiomatosis (PCH) 
 
Group 2 – Pulmonary hypertension due to left heart disease (including systolic and 
diastolic dysfunction, mitral or aortic valvular disease) 
 
Group 3 – Pulmonary hypertension secondary to lung diseases and/or hypoxia 
 
Group 4 – Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
Group 5 – Miscellaneous - including hematologic disorders, sarcoidosis, pulmonary 
Langerhans cell histiocytosis, metabolic disorders, etc. 
 
(Modified from Ref. 5) 
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Table 2. Baseline Characteristics 
 
 Historical control 
group 
IIT group P value 
Patient number 8 13  
Age (years old)  52 ± 18 42 ± 8 n.s. 
Male / Female 0 / 8 1 / 12 n.s. 
Vasodilator therapy    
  Beraprost 6 9 n.s. 
  Epoprostenol 3 2 n.s. 
  Bosentan 4 5 n.s. 
  PDE-5 inhibitors 0 6 <0.05 
Observational periods (days) 914 ± 456 565 ± 431 n.s. 
Hemodynamics    
  Mean PAP 43.5 ± 16.3 39.5 ± 9.2 n.s. 
  PVR 1131 ± 898 700 ± 434 n.s. 
Blood test    
  BNP (pg/dL) 303 ± 290 201 ± 398 n.s. 
  CRP (mg/dL) 0.65 ± 0.74 0.20 ± 0.22 n.s. 
WHO functional class   n.s. 
  I 0 2  
  II 4 6  
  III 3 5  
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  IV 1 0  
6 minute walking distance 358 ± 27 442 ± 54 <0.05 
Values are expressed as mean ± SD.  BNP, type B natriuretic peptide; CRP, C-reactive 
protein; IIT, intensive immunosuppressive therapy; IV, intravenous; n.s., not significant; PAP, 
pulmonary arterial pressure; PDE-5 inhibitors, phosphodiesterase type 5 inhibitors (sildenafil 
and tadalafil); PVR, pulmonary vascular resistance.   
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